Search Site

Trends banner

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

Equinor signs $27 bn gas deal

The 10-year contract was signed with Centrica.

ADNOC Drilling secures $1.15bn contract

The contract for two jack-up rigs begins in the second quarter.

Etihad Q1 profit $187 million

This is a 30% YoY increase over Q1 2025.

Yalla Group Q1 revenue $83m

Net income rose to $36.4 million, a 17% YoY increase.

UAE children aged 3-17 to receive Chinese Sinopharm vaccine

    • The Gulf state, which has among the world’s highest immunization rates, was already providing the Pfizer-BioNTech vaccine for children aged 12-15

    • The UAE government took to twitter to make the announcement

    The United Arab Emirates has decided to inoculate children between the ages of 3 and 17 with Chinese Covid-19 vaccine Sinopharm. Although the Chinese vaccines have been criticized for their low efficacy, the UAE was still going ahead to vaccinate the younger children with the Sinopharm vaccine.

    The UAE government took to twitter to make the announcement. It cited the health ministry as saying the decision comes after clinical trials and extensive evaluations, without providing any details. Authorities said in June the trial would monitor the immune response of 900 children.

    The Gulf state, which has among the world’s highest immunization rates, was already providing the Pfizer-BioNTech vaccine for children aged 12-15.

    The health ministry said on Sunday that 78.95 percent of the UAE population of roughly 9 million had received one vaccine dose while 70.57 percent had been fully vaccinated.

    The UAE, the region’s tourism and trade hub, registered 1,519 new coronavirus infections on Sunday to take its total to 682,377 cases and 1,951 deaths. It does not provide a breakdown for each of its seven emirates.

    It led Phase III clinical trials of the vaccine produced by China’s state-owned drugmaker Sinopharm and has started manufacturing it under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42.